Sign in
DFTX Stock Price, Chart, Stats & News
Definium Therapeutics, Inc.
Save
4.00B
Market cap
–
Current P/E
–
Forward P/E
DFTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -41.76% |
ROE | -84.39% |
D/E | – |
Interest coverage ratio | -11.96x |
DFTX valuation
P/E | – |
P/S | – |
P/B | 4.81x |
P/CF | -12.24x |
P/FCF | -13.66x |
P/OCF | -12.24x |
PEG | 1.70x |
EV multiple | -12.01x |
About
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder.
Similar securities
Based on sector and market capitalization
Report issue